Patients with familial hypercholesterolaemia show enhanced spontaneous chemokine release from peripheral blood mononuclear cells ex vivo
|
|
- Nathaniel Cross
- 6 years ago
- Views:
Transcription
1 European Heart Journal (2003) 24, Clinical research Patients with familial hypercholesterolaemia show enhanced spontaneous chemokine release from peripheral blood mononuclear cells ex vivo Dependency of xanthomas/xanthelasms, smoking and gender Kirsten B. Holven a,b,c, Anne M. Myhre a,b,pål Aukrust b,d, Tor Arne Hagve e, Leiv Ose a, Marit S. Nenseter a,b,c * a Lipid Clinic, Rikshospitalet University Hospital, Oslo, Norway b Research Institute for Internal Medicine, Rikshospitalet University Hospital, Oslo, Norway c MSD Cardiovascular Research Center, Rikshospitalet University Hospital, Oslo, Norway d Section of Clinical Immunology and Infection Diseases, Medical Department, Rikshospitalet University Hospital, Oslo, Norway e Institute for Clinical Biochemistry, Rikshospitalet University Hospital, Oslo, Norway Received 12 March 2003; received in revised form 27 June 2003; accepted 31 July 2003 KEYWORDS Familial hypercholesterolaemia; Premature coronary artery disease; Xanthomas/xanthelasms; Chemokines Aims Familial hypercholesterolaemia (FH) is associated with increased risk of premature atherosclerosis and coronary artery disease (CAD). However, onset of clinically manifested CAD varies widely among patients with heterozygous FH, and we hypothesized that inflammatory mediators such as chemokines could contribute to atherogenesis in these patients. Methods and results We compared peripheral blood mononuclear cells (PBMCs) from FH patients with an identical mutation with PBMCs from sex- and age-matched healthy controls with respect to spontaneous and oxidized low density lipoprotein (oxldl)- stimulated release of chemokines. Our main findings were: (1) PBMCs from FH patients spontaneously released significantly higher levels of macrophage inflammatory protein (MIP)-1α, MIP-1β and interleukin (IL)-8, and had a significantly lower oxldl-stimulatory ratio for MIP-1α and MIP-1β than cells from healthy controls. (2) Spontaneous release of these chemokines correlated positively and stimulatory ratio correlated negatively with plasma concentrations of total and LDL cholesterol. (3) Among FH patients, release of MIP-1α, MIP-1β and IL-8 from PBMCs varied with the presence of xanthomas/xanthelasms, smoking and gender. (4) In vitro studies showed that FH serum but not control serum was able to induce enhanced spontaneous release of chemokines in PBMCs from both FH patients and control subjects. Conclusions Our data may suggest that a pathophysiological consequence of FH is enhanced chemokine responses, which in turn may promote recruitment and activation of leukocytes within the vessel wall, contributing to atherosclerosis as well as to the different phenotypes in these patients with an identical FH mutation The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved. * Correspondence to: Marit S. Nenseter, Senior Research Scientist, Research Institute for Internal Medicine, Rikshospitalet University Hospital, 0027 Oslo, Norway. Tel: ; Fax: address: maritn@klinmed.uio.no (M.S. Nenseter) X/03/$ - see front matter 2003 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved. doi: /s x(03)
2 Chemokine release in familial hypercholesterolaemia 1757 Table 1 Characteristics of the study group FH patients (n=22) Control subjects (n=15) Female/male (n/n) 8/14 6/9 Age (years) 43.9± ±14.0 Body mass index (kg/m 2 ) 26.3±4.1 a 22.1±2.5 Premature coronary artery disease (n) 6 0 Tendon xanthomas/xanthelasms present (n) 10 0 Corneal arcus present (n) 5 0 Antihypertensive treatment (n) 4 0 Diabetes (n) 1 0 Current smokers (n) 9 3 Total cholesterol (mmol/l) 9.3±1.5 b 4.6±1.0 LDL cholesterol (mmol/l) 7.6±1.4 b 2.9±0.8 HDL cholesterol (mmol/l) 1.3± ±0.3 Triglycerides (mmol/l) 1.3 ( ) b 0.8 ( ) Lipoprotein (a) (mg/l) 150 (<96 787) 159 (<96 648) Apolipoprotein B (g/l) 2.0±0.4 a 0.9±0.2 Apolipoprotein A I (g/l) 1.3± ±0.2 Homocysteine (µmol/l) 9.5 (6 17) 10.0 (6 13) Data are presented as means±sd or mediam (range). a P<0.02 and b P<0.001 vs control subjects; n indicates number of individuals. LDL-cholesterol was calculated in 20 FH patients. Introduction Familial hypercholesterolaemia (FH) is caused by mutations in the low density lipoprotein (LDL)-receptor gene, and is associated with increased risk of premature atherosclerosis and coronary artery disease (CAD). 1 However, the onset of clinically manifested CAD varies widely among patients with heterozygous FH, even among carriers of an identical mutation. 2,3 Hence, the variation seen in the phenotypes among these patients cannot exclusively be explained from their genotype. These findings indicate that factors other than genotype also are of importance for development of atherosclerosis and onset of CAD symptoms among FH patients. Several lines of evidence suggest that inflammatory processes play an important role in the pathogenesis of atherosclerosis. 4 7 Thus, the migration of monocytes into the intima is a central step in the early development of atherosclerosis, and extensive infiltration of bloodderived macrophages and T-cells into the vessel wall is seen in the active stages of this disorder. Chemokines or chemotactic cytokines seem to play a major role in this recruitment and activation of leukocytes into atherosclerotic plaque as suggested by several studies in animal models. 8,9 Raised plasma levels of chemokines have also been reported in CAD patients with particular high levels in those with unstable disease, further supporting a pathogenic role for these cytokines in CAD One might hypothesize that chemokines also could be involved in the atherogenesis in FH patients possibly contributing to differences in phenotypes between these individuals, but at present few studies have investigated chemokine production in FH. In the present study we investigated the role of chemokines in FH patients by comparing peripheral blood mononuclear cells (PBMCs) obtained from FH patients and sex- and age-matched healthy control subjects with respect to spontaneous and oxidized LDL (oxldl)-stimulated release of CC- and CXCchemokines. Methods Subjects Twenty-two adults <75 years of age with FH were recruited at the Lipid Clinic, Rikshospitalet University Hospital, Norway (Table 1). All subjects were diagnosed with definite FH by DNA test. Six of the FH patients had diagnosed premature CAD, defined as myocardial infarction at an age of 50. The diagnosis of CAD was confirmed in all these patients by coronary angiography showing 1-vessel disease (>75% narrowing of luminal diameter). Sixteen out of 22 patients were on atorvastatin treatment, whereas six were on simvastatin or lovastatin. Prior to blood sampling they had a 4-week washout period without statin treatment to obtain LDL-cholesterol concentrations on baseline levels. Although we have no information about the effect of the washout period on chemokine concentrations, it is conceivable that no statin-mediated effect on chemokine levels will persist after such a period. Control subjects were 15 healthy sex- and age-matched volunteers recruited among the staff at Rikshopitalet University Hospital, with no history of hypertension, diabetes, CAD or other acute or chronic illness (Table 1). The study complies with the Declaration of Helsinki, and the study protocol was approved by the Regional Committee of Medical Ethics. Informed consent was obtained from all subjects. Venous blood samples were collected after an overnight fast. Plasma and serum samples were collected, divided into aliquots and stored at 80 C until analysis as previously described. 13 PBMCs was isolated immediately (see below). Release of chemokines from PBMCs Peripheral blood mononuclear cells were obtained from heparinized blood by isopaque-ficoll (Lymphoprep, Nycomed Pharma AS, Oslo, Norway) gradient centrifugation within 45 min.
3 1758 K.B. Holven et al. PBMCs were incubated in flat-bottomed 96-well trays (Costar, Corning Inc., Corning, NY; /ml; 100 µl/well) in medium alone (RPMI-1640 containing 2 mm l-glutamine [Sigma Chemical Co., St. Louis, MO], supplemented with 100 U/ml penicillin and 5% autologous serum), or with oxldl (final concentration 100 µg/ml). Cell-free supernatants were harvested after culturing for 24 h, divided into aliquots, and stored at 80 C until analysis. Isolation and oxidation of LDL Plasma from healthy blood donors, collected in endotoxin-free heparin, was stored in 0.6% sucrose at 80 C. LDL was isolated by sequential ultracentrifugation and was oxidized in the presence of freshly prepared 5 µm CuSO 4 (final concentration) as described previously. 14 Oxidized LDL contained 669±12 nmol lipid peroxides per mg LDL protein; and relative electrophoretic mobility was 4.5±0.2 (n=3). Low-density lipoprotein preparations were free of endotoxin, as determined by the Limulus assay. 15 OxLDL was stored under N 2 and used within 2 weeks for stimulation of PBMCs (see above). Enzyme immunoassays (EIAs) Concentrations of monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, MIP-1β, interleukin (IL)-8, and epithelial neutrophil activating peptide (ENA)-78 were measured by EIA from R&D systems (Minneapolis, MN). To minimize run-to-run variability, all samples from a given patient were analysed in the same micro-titre plate. Routine laboratory assays Standard blood chemistry and lipid parameters was measured in serum/plasma using routine laboratory methods. Statistical analysis Data are given as means±sd or medians and 25th 75th percentiles when data were skewed. Data from FH patients and control subjects were compared by the Student t test. When the data were not normally distributed (e.g., chemokine data), the data were subjected to logarithmic transformation before the parametric analysis. Pearson s chi-square test was used for the Lipoprotein (a) data. Associations between variables were tested by Pearson correlation coefficients. The level of statistical significance was set at P<0.05. Results Characterization of subjects Biological characterization of the participants is shown in Table 1. All FH patients had FH-elverum, the most common Norwegian LDL-receptor mutation, with a frequency of 28%. 16 FH-elverum is a splice site mutation, located in the ligand binding domain of the receptor. 16 Compared to healthy controls, FH patients had significantly higher body mass index and significantly higher plasma concentrations of total- and LDL-cholesterol, triglycerides, and apo B, whereas no significant differences were found in high density lipoprotein (HDL)-cholesterol, apo A-I and lipoprotein (a) (Table 1). Furthermore, no significant differences were observed in plasma concentrations of creatinine, urea, total protein, ASAT, ALAT, creatine kinase, high-sensitivity C-reactive protein, folate, and vitamin B 12 (data not shown). Serum concentrations of chemokines There were no significant differences in serum concentrations of MCP-1, MIP-1β and ENA-78 between FH patients (369 pg/ml [ pg/ml], 175 pg/ml [ pg/ml] and 1230 pg/ml [ pg/ml], respectively) and control subjects (429 pg/ml [ pg/ml], 129 pg/ml [ pg/ml] and 1257 pg/ml [ pg/ml], respectively). Furthermore, serum concentrations of MCP-1, MIP-1β and ENA-78 did not correlate with plasma concentrations of total and LDL-cholesterol. Release of chemokines from PBMCs ex vivo We next examined the release of chemokines from unstimulated and oxldl-stimulated PBMCs in FH patients and healthy controls after culturing cells for 24 h. To better reflect the in vivo conditions, PBMCs were incubated in medium containing autologous serum (5%) from each individual. Several significant findings were revealed. First, unstimulated PBMCs from FH patients released markedly enhanced levels of MIP-1α, MIP-1β and IL-8 comparing cells from healthy controls (Fig. 1). Second, oxldl significantly enhanced the release of these chemokines both in FH patients and in healthy controls (Fig. 1), and although the oxldl-stimulated levels tended to be higher in FH group, this differences did not reach statistical significance (Fig. 1). In contrast, the stimulatory ratio (oxldl-stimulated/unstimulated) was lower in FH patients compared with healthy controls for both MIP-1α: (3.4 [1 5] vs 4.9 [4 6], P=0.04), MIP-1β (1.7 [1 6] vs 5.8 [3 11], P=0.02), and IL-8: (9.7 [4 101] vs 72 [11 159], P=0.067). As for ENA-78, no significant difference was seen between FH patients and control subjects in either spontaneous or oxldl-stimulated release (Fig. 1E) or in the oxldl-stimulatory ratio (2.2 [2 4] vs 1.8 [1 3], respectively). Correlations between the release of chemokine and lipid and clinical parameters Interestingly, plasma total and LDL-cholesterol correlated positively with spontaneous release of MIP-1α, MIP-1β and IL-8, and total cholesterol correlated negatively with the stimulatory ratio for MIP-1α, MIP-1β and IL-8 (Table 2). No such correlations were observed between cholesterol and release of ENA-78. While there were no significant differences in the release of chemokines between PBMCs from FH patients with (n=6) or without (n=16) premature CAD (Table 3), PBMCs from FH patients with tendon xanthomas and/or xanthelasms (n=10) spontaneously released higher amounts of MIP-1α, MIP-1β and IL-8, as well as higher amounts of oxldl-induced MIP-1α and IL-8 than cells from FH patients without (n=12) this manifestation (Table 3). Furthermore, compared to PBMCs from nonsmoking FH patients (n=13), PBMCs from cigarettesmoking FH patients (n=9) spontaneously released higher
4 Chemokine release in familial hypercholesterolaemia 1759 Fig. 1 The release of the CC-chemokines MIP-1α (A), MIP-1β (B), and the CXC-chemokines IL-8 (C), and ENA-78 (D) from unstimulated (Unstim) and oxldl-stimulated (OxLDL) peripheral blood mononuclear cells (PBMCs) ex vivo, isolated from healthy control subjects (Ctr) and patients with familial hypercholesterolaemia (FH). Compared to unstimulated PBMCs, oxldl-stimulated PBMCs released more of all four chemokines (P<0.001, except P=0.078 for MIP-1β). Horizontal bars represent median values. Table 2 Correlation coefficients (r) between total and LDL cholesterol levels and release of chemokines from PBMC obtained from FH patients (n=22) and healthy control subjects (n=15) Total cholesterol LDL cholesterol r P-value r P-value MIP-1α unstimulated stimulatory ratio a MIP-1β unstimulated stimulatory ratio IL-8 unstimulated stimulatory ratio a Stimulatory ratio indicates oxldl-stimulated/unstimulated release of chemokines. IL-8 levels and had decreased stimulatory ratio for MIP-1α and IL-8 (Table 3). Likewise, PBMCs from smoking healthy controls (n=3) spontaneously released higher levels of MIP-1α, MIP-1β and IL-8 (50 pg/ml [ pg/ml], 83 pg/ml [ pg/ml] and 597 pg/ml [ pg/ ml], respectively), comparing cells from non-smoking (n=12) controls (16 pg/ml [11 22 pg/ml], 15 pg/ml [4 53 pg/ml] and 10 pg/ml [ pg/ml], respectively; P 0.02 for all). Finally, compared to PBMCs from female FH patients (n=8), the stimulatory ratio for MIP-1α, MIP-1β and IL-8 was lower in cells from male FH patients (n=14; Table 3). No such pattern related to gender was seen in healthy controls. As for ENA-78, we found no relationship with either xanthomas/xanthelasms, cigarette-smoking or gender. Effect of serum on spontaneous release of chemokines from PBMCs ex vivo To further explore the finding that PBMCs from FH patients, cultured in the presence of autologous serum,
5 Table 3 Relationship between the release of chemokines from PBMC and premature CAD, xanthomas/xanthelasms, smoking and gender among FH-patients (n=22) Premature CAD Xanthomas/xanthelasms Smoking Gender Present (n=6) Not present (n=16) Present (n=10) Not present (n=12) Smokers (n=9) Non-smokers (n=13) Male (n=14) Female (n=8) MIP-1α unstimulated 106 (28 449) 23 (15 309) 268 (32 499) a 20 (13 46) 82 (28 455) 20 (15 295) 66 (20 449) 19 (14 146) (pg/ml) stimulatory ratio 2.6 (1 5) 4.2 (1 5) 1.8 (1 3) 4.7 (2 6) 1.3 (1 4) b 4.6 (2 6) 1.8 (1 5) b 4.7 (3 7) MIP-1β unstimulated 219 (41 800) 72 (30 518) 298 ( ) a 34 (18 189) 232 ( ) 50 (28 487) 214 (58 800) 43 (30 445) (pg/ml) stimulatory ratio 1.0 (0.4 5) 2.4 (1 7) 1.2 (1 2) 3.6 (1 9) 1.4 (1 6) 2.0 (1 8) 1.2 (0.4 3) a 5.2 (2 12) IL-8 unstimulated 526 ( ) 248 ( ) 3521 ( ) a 10 (10 536) 3202 ( ) b 10 ( ) 1874 ( ) 21 ( ) (pg/ml) stimulatory ratio 9.7 (6 57) 15.8 (4 136) 5.7 (3 6) 68 (16 136) 5.7 (1 16) b 60 (6 140) 6.0 (1 53) c 88 (11 136) Data are given as median (25th 75th percentiles). a P b P 0.05 and c P=0.058 vs FH patients without this characteristic. n indicates number of individuals; stimulatory ratio indicates oxldl-stimulated/unstimulated release of chemokines K.B. Holven et al.
6 Chemokine release in familial hypercholesterolaemia 1761 Fig. 2 Effect of serum on spontaneous release of the CC-chemokine MCP-1 (A) and the CXC-chemokine IL-8 (B) from PBMCs ex vivo, isolated from healthy control subjects (Ctr; n=3) and patients with familial hypercholesterolaemia (FH; n=3). The cells were incubated in the presence of heat-inactivated serum from a FH patient (FH-serum) or a control subject (Ctr-serum). Horizontal bars represent median values. spontaneously released a high level of chemokines, we cultured PBMCs from patients with FH-elverum (n=3) in the presence of serum from a FH patient or from a control subject. Similarly, PBMCs from control subjects (n=3) were cultured for 24 h under the same conditions. Interestingly, in the presence of serum from the FH patient, PBMCs from FH patients as well as from control subjects spontaneously released enhanced levels of MCP-1 and IL-8, with particular high levels in FH patients (Fig. 2). In contrast, serum from the control subject had no enhancing effect on chemokine release either in FH PBMCs or in control PBMCs (Fig. 2). Discussion The present study shows that: (1) PBMCs obtained from FH patients spontaneously released significantly higher levels of MIP-1α, MIP-1β and IL-8, and had significantly lower oxldl-stimulatory ratio for MIP-1αand MIP-1β than cells from healthy controls. (2) The spontaneous release of these chemokines correlated positively and the stimulatory ratio correlated negatively with plasma concentrations of total and LDL cholesterol. (3) Among FH patients, the release of MIP-1α, MIP-1β and IL-8 from PBMCs varied with the presence of xanthomas/ xanthelasms, smoking habits and gender. (4) In vitro studies showed that FH serum but not control serum was able to induce enhanced spontaneous release of chemokines in PBMCs from both FH patients and control subjects. Taken together, our data may suggest that a pathophysiological consequence of FH is enhanced chemokine responses, which in turn may promote recruitment and activation of leukocytes within the vessel wall, contributing to atherosclerosis as well as to the different phenotypes in these patients. In the present study we show that PBMCs from FH patients cultured in the presence of autologous serum spontaneously released higher levels of chemokines accompanied by a decrease in the stimulatory response to oxldl, as assessed by stimulatory ratio, compared with PBMCs from healthy controls. Such a pattern may suggest in vivo activation of these cells in FH patients, and if such enhanced release of chemokines also exists within the vessel wall it may clearly reflect important pathogenic processes in these individuals. Thus, migration and activation of leukocytes is an important event in the development of atherosclerosis, and chemokines may play a crucial role in this process. 4 13,18 22 Accordingly, enhanced expression of MCP-1, IL-8, MIP-1α and MIP-1β has been found in human coronary atheroma. 7,12,18 21 Furthermore, intimal macrophages with enhanced expression of the IL-8 receptor (i.e. CXCR2) have been reported in murine and human atherosclerotic lesions. 8,12 Also, knockout mice lacking the MCP-1 receptor (i.e. CCR2) have reduced progression of atherosclerosis. 8,9 Recently, enhanced gene expression of MIP-1α, MIP-1β and their corresponding receptors CCR1 and CCR5 was found in PBMCs from CAD patients compared to cells from healthy control subjects. 22 Interestingly, MIP-1α and MIP-1β co-localize in atherosclerotic plaques, and are expressed by T-cells in macrophage/ foam cell-rich areas of the plaque, suggesting cross-talk between T-cells and macrophages through chemokine signalling, resulting in movement of macrophages to the appropriate inflammatory areas. 7 Moreover, studies in CCR1 knockout mice indicate the involvement of MIP-α in the pathogenesis of allograft atherosclerosis. 23 MIP-1β has been shown to increase the activity of tissue factor, a potent initiator of coagulation, suggesting that this chemokine could mediate both inflammatory and thrombotic responses within an atherosclerotic plaque. 24 Our findings in the present study further support a possible role of these mediators in the atherogenesis of FH patients. The specific underlying molecular defect of the LDLreceptor gene may contribute to the phenotypic variance seen in the onset of CAD in patients with heterozygous FH. 17 In the present study we selected participants with identical gene mutation (FH-elverum). In spite of this, there were large individual variations in total and LDLcholesterol levels as well as in release of chemokines.
7 1762 K.B. Holven et al. Interestingly, we found that FH serum, but not serum from healthy controls, were able to enhance the release of chemokines in PBMCs in both FH patients and controls. Moreover, the highest spontaneous release of chemokines and the lowest oxldl-stimulatory ratio was found in PB- MCs from FH patients with the highest serum levels of total and LDL-cholesterol. However, despite the use of FH serum, PBMCs in FH patients still had a higher chemokine secretion than cells in healthy individuals, suggesting that the cellular factor also contribute to the enhanced chemokine release of FH patients. Nevertheless, these data may suggest that lipid loading of the cells could explain some of the inflammatory responses observed. Moreover, these findings in these transgenic individuals further support a link between lipids and inflammation, and support the notion that LDL- and in particular oxldl-cholesterol may be important stimuli for the inflammatory response in atherosclerotic disorders. Among FH patients PBMCs from smokers spontaneously released higher levels of chemokines and had decreased oxldl-stimulatory ratio comparing non-smoking FH patients. Similar differences appeared between smokers and non-smokers in the control group, suggesting a link between smoking and enhanced chemokine levels as a more general phenomenon. Furthermore, in FH patients, but not in healthy controls, men had significantly decreased oxldl-stimulatory ratio for MIP-1α, MIP-1β and IL-8 comparing FH women. We were unable to show any differences in markers of inflammation among those with clinically manifest premature CAD compared to those without. This could be due to too low number of CAD patients (n=6) to provide adequate power in this substudy. However, PBMCs from FH patients with tendon xanthomas/xanthelasms had enhanced spontaneous release of chemokines compared to those without tendon xanthomas/xanthelasms. Taken together, these data show that MIP-1α, MIP-1β and IL-8 are associated with established risk factors for CAD and suggest that these chemokines may be additional factors contributing to accelerated atherosclerosis as well as to the different phenotypes in this group of high-risk patients with identical FH mutation. Acknowledgements We thank Eilen Strand for expert technical assistance. This work was supported by grants from The Norwegian Research Council, The Norwegian Foundation for Health and Rehabilitation, and University of Oslo, Norway. References 1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232: Scientific Steering Committee on Behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303: Jansen AC, van Wissen S, Defesche JC et al. Phenotypic variability in familial hypercholesterolaemia: an update. Curr Opin Lipidol 2002; 13: Gerald C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: Gerszten RE, Mach F, Sauty A et al. Chemokines, leukocytes and atherosclerosis. J Lab Clin Med 2000;136: Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol 1998;9: Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 1999;147: Boisvert WA, Santiago R, Curtiss LK et al. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998;101: Dawson TC, Kuziel WA, Osahar TA et al. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 1999;143: Riesenberg K, Levy R, Katz A et al. Neutrophil superoxide release and interleukin 8 in myocardial infarction: Distinction between complicated and uncomplicated states. Eur J Clin Invest 1997;27: Matsumori A, Furukawi Y, Hashimoto T et al. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol 1997;29: Boisvert WA, Curtiss LK, Terkeltaub RA. Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol Res 2000;21: Aukrust P, Berge RK, Ueland T et al. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol 2001;37: Brude IR, Drevon CA, Hjermann I et al. Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants. Arterioscler Thromb Vasc Biol 1997;17: Brandtzaeg P, Kierulf P, Gaustad P et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989;159: Leren TP, Solberg K, Rodningen OK et al. Two founder mutations in the LDL receptor gene in Norwegian familial hypercholesterolemia subjects. Atherosclerosis 1994;111: Yamamoto A, Kamiya T, Yamamura T et al. Clinical features of familial hypercholesterolemia. Arteriosclerosis 1989;9:I Hayes IM, Jordan NJ, Towers S et al. Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb Vasc Biol 1998;18: Nelken NA, Coughlin SR, Gordon D et al. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991;88: Yla-Herttuala S, Lipton BA, Rosenfeld ME et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991; 88: Wang N, Tabas I, Winchester R et al. Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. J Biol Chem 1996;271: Waehre T, Damas JK, Gullestad L et al. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. JAm Coll Cardiol 2003;41: Gao W, Topham PS, King JA et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000;105: Schecter AD, Calderon TM, Berman AB et al. Human vascular smooth muscle cells possess functional CCR5. J Biol Chem 2000;275:
An elevated plasma level of homocysteine is an independent
Folic Acid Treatment Reduces Chemokine Release From Peripheral Blood Mononuclear Cells in Hyperhomocysteinemic Subjects Kirsten B. Holven, Pål Aukrust, Torbjørn Holm, Leiv Ose, Marit S. Nenseter Abstract
More informationAtherosclerosis 214 (2011) Contents lists available at ScienceDirect. Atherosclerosis
Atherosclerosis 214 (2011) 163 168 Contents lists available at ScienceDirect Atherosclerosis journal homepage: www.elsevier.com/locate/atherosclerosis Children with familial hypercholesterolemia are characterized
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationAppendix F Simon Broome Diagnostic criteria for index individuals and relatives
Appendix F Simon Broome Diagnostic criteria for index individuals and relatives 1 SIMON BROOME DIAGNOSTIC CRITERIA FOR INDEX INDIVIDUALS (PROBANDS) 2 2 GENDER- AND AGE-SPECIFIC LDL-C CRITERIA FOR THE DIAGNOSIS
More informationIncreased Expression of Interleukin-1 in Coronary Artery Disease With Downregulatory Effects of HMG-CoA Reductase Inhibitors
Increased Expression of Interleukin-1 in Coronary Artery Disease With Downregulatory Effects of HMG-CoA Reductase Inhibitors Torgun Wæhre, MD; Arne Yndestad, MSc; Camilla Smith, MD; Terje Haug, PhD; Siv
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationOriginal Article. prior to (n = 42) and after statin treatment (n = 10) and in controls (n = 25) by quantitative real-time polymerase chain reaction.
Original Article doi:./j.365-796..584.x Oxidized LDL level is related to gene expression of tumour necrosis factor super family members in children and young adults with familial hypercholesterolaemia
More informationFamilial hypercholesterolemia (FH) is caused by a mutation
Chemokines in Children With Heterozygous Familiar Hypercholesterolemia Selective Upregulation of RANTES Kirsten B. Holven, Jan K. Damås, Arne Yndestad, Torgun Wæhre, Thor Ueland, Bente Halvorsen, Lars
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationIdentification and management of familial hypercholesterolaemia (FH) - An overview
Identification and management of familial hypercholesterolaemia (FH) - An overview National Collaborating Centre for Primary Care and Royal College of General Practitioners NICE Guideline CG 71 (August
More informationDyslipidemia Endothelial dysfunction Free radicals Immunologic
ATHEROSCLEROSIS Hossein Mehrani Professor of Clinical Biochemistry Definition Atherosclerosis: Is a chronic inflammatory process characterized by plaque formation within the vessel wall of arteries and
More informationPCSK9 Inhibition: From Genetics to Patients
PCSK9 Inhibition: From Genetics to Patients John Chapman BSc, Ph.D., D.Sc., FESC Research Professor, University of Pierre and Marie Curie Director Emeritus, INSERM Dyslipidemia and Atherosclerosis Research
More informationFamilial hypercholesterolaemia in children and adolescents
Familial hypercholesterolaemia in children and adolescents Rationale and recommendations for early identification and treatment European Atherosclerosis Society Consensus Panel Slide deck adapted from:
More information4/14/2018 DYSLIPIDEMIA CASES. Mary Malloy, MD. I have nothing to disclose
DYSLIPIDEMIA CASES Mary Malloy, MD I have nothing to disclose 1 Case 1 A 24 year old healthy, slender woman is referred because she has a family history of premature CAD (mother, age 59, had onset of angina
More informationIncreased Levels of Neutrophil-Activating Peptide-2 in Acute Coronary Syndromes Possible Role of Platelet-Mediated Vascular Inflammation
Journal of the American College of Cardiology Vol. 48, No. 8, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.06.060
More informationFamilial hypercholesterolaemia
Familial hypercholesterolaemia Jaimini Cegla MRCP FRCPath PhD Consultant in Chemical Pathology and Metabolic Medicine Hammersmith Hospital Lipid Clinic 20 April 2017 An unrecognised, potentially fatal,
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationLipid Metabolism in Familial Hypercholesterolemia
Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationMetabolism and Atherogenic Properties of LDL
Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationEzetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)
Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry
More informationMortality and cardiovascular morbidity in patients with familial hypercholesterolemia
Mortality and cardiovascular morbidity in patients with familial hypercholesterolemia PhD Thesis Liv J Mundal UNIVERSITY OF OSLO 2016 Liv J Mundal, 2016 Series of dissertations submitted to the Faculty
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationStatin, Pleiotropic effect, Oxidized low-density lipoprotein
Effects of Statins on Circulating Oxidized Low-density Lipoprotein in Patients With Hypercholesterolemia Shigenobu INAMI, 1 MD, Kentaro OKAMATSU, 1 MD, Masamichi TAKANO, 1 MD, Gen TAKAGI, 1 MD, Shunta
More informationLipid metabolism in familial hypercholesterolemia
Lipid metabolism in familial hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationAtherosclerosis 216 (2011) Contents lists available at ScienceDirect. Atherosclerosis
Atherosclerosis 216 (2011) 426 432 Contents lists available at ScienceDirect Atherosclerosis journal homepage: www.elsevier.com/locate/atherosclerosis Lipoprotein(a) levels in coronary heart disease-susceptible
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationLp(a) Ready for prime time? E Stroes AMC
Lp(a) Ready for prime time? E Stroes AMC Case Male, 45 years old Hypertension: DM: Smoking: Dyslipidemia: Fam history: brother MI (55yr) Lipoprotein(a): 1240 mg/l!!! Lipoprotein(a) = LDL + apo(a) tail
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationFocus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013
Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013 Conflicts CMO for The FH Foundation Pre-talk quiz What is cascade screening? 1. screening all family members 2.
More informationAn educational booklet for patients with familial hypercholesterolemia DR. LEIV OSE
An educational booklet for patients with familial hypercholesterolemia DR. LEIV OSE CONTENTS WHAT WILL YOU LEARN FROM THIS BOOKLET? You will learn about Familial Hypercholesterolemia, its cause, and the
More informationStudy of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease
Original article: Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease Dr Sonu Yadav, Dr Abhijit Nikam, Dr Vivek Chiddarwar, Dr A L Kakrani Department of Medicine,
More informationLeptin deficiency suppresses progression of atherosclerosis in apoe-deficient mice
Leptin deficiency suppresses progression of atherosclerosis in apoe-deficient mice Atherosclerosis, 2007 Chiba T, Shinozaki S, Nakazawa T, et al. Present by Sudaporn Pummoung Apolipoprotein E (apoe( apoe)
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationThe apolipoprotein story
Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationRelationship between serum glutathione peroxidase-1activity with endothelial dysfunction level in patients with coronary artery diseases
Relationship between serum glutathione peroxidase-1activity with endothelial dysfunction level in patients with coronary artery diseases Introduction Reactive oxygen species (ROS),such as superoxide and
More informationCascade Screening for FH: the U.S. experience
Cascade Screening for FH: the U.S. experience Paul N. Hopkins, MD, MSPH Professor of Internal Medicine Cardiovascular Genetics University of Utah Disclosures Consultant Genzyme, Amgen, Regeneron Research
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationMechanisms of Action for Arsenic in Cardiovascular Toxicity and Implications for Risk Assessment
Mechanisms of Action for Arsenic in Cardiovascular Toxicity and Implications for Risk Assessment Mandeep Sidhu, MD, MBA, FACC Assistant Professor of Medicine Division of Cardiology Albany Medical College
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationMeasurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date
MP 2.04.22 Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationRole of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD
Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal
More informationSummary and concluding remarks
Summary and concluding remarks This thesis is focused on the role and interaction of different cholesterol and phospholipid transporters. Cholesterol homeostasis is accomplished via a tightly regulated
More informationCitation for published version (APA): Sivapalaratnam, S. (2012). The molecular basis of early onset cardiovascular disease
UvA-DARE (Digital Academic Repository) The molecular basis of early onset cardiovascular disease Sivapalaratnam, S. Link to publication Citation for published version (APA): Sivapalaratnam, S. (2012).
More informationLIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 : EFFECTS OF LOW DENSITY LIPOPROTEIN APHERESIS
LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 : EFFECTS OF LOW DENSITY LIPOPROTEIN APHERESIS Patrick M. Moriarty, M.D., FACP, Director, Atherosclerosis and LDL-Apheresis Center, University of Kansas Medical
More informationDepartment of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, Japan. 4
146 Journal of Atherosclerosis and Thrombosis Original Articles Vol. 11, No. 3 Clinical Features of Familial Hypercholesterolemia in Japan in a Database from 1996 1998 by the Research Committee of the
More informationDecreased Inflammatory Markers in Diabetic Patients with Angiographically Proved Coronary Artery Disease after 18 Months of Statins Therapy
Decreased Inflammatory Markers in Diabetic Patients with Angiographically Proved Coronary Artery Disease after 18 Months of Statins Therapy DANIEL LIGHEZAN, ROXANA BUZAS, CORINA SERBAN, IOANA SUCEAVA University
More informationMonocyte chemoattractant protein-1 in patients with peripheral arterial disease
Short Communication Mediators of Inflammation, 13(1), 39/43 (February 2004) Background: Chemokine-driven migration of inflammatory cells has been implicated in the pathogenesis of atherosclerotic conditions
More informationBiochemical, Molecular, and Genetic Mechanisms
Biochemical, Molecular, and Genetic Mechanisms Triglyceride-Rich HDL 3 from Patients with Familial Hypercholesterolemia Are Less Able to Inhibit Cytokine Release or to Promote Cholesterol Efflux 1 Inger
More informationREAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING
REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND
More informationStudy of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases
Original article: Study of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases Dr Abhijit Nikam, Dr Sonu Yadav, Dr Vivek Chiddarwar, Dr A L Kakrani Dept of Medicine,
More informationLipid Lowering in Patients at High Risk for Cardiovascular Disease
Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel
More informationLipid/Lipoprotein Structure and Metabolism (Overview)
Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures
More informationAcute coronary syndrome. Dr LM Murray Chemical Pathology Block SA
Acute coronary syndrome Dr LM Murray Chemical Pathology Block SA13-2014 Acute myocardial infarction (MI) MI is still the leading cause of death in many countries It is characterized by severe chest pain,
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationPathology of Coronary Artery Disease
Pathology of Coronary Artery Disease Seth J. Kligerman, MD Pathology of Coronary Artery Disease Seth Kligerman, MD Assistant Professor Medical Director of MRI University of Maryland Department of Radiology
More information902 Biomed Environ Sci, 2014; 27(11):
902 Biomed Environ Sci, 2014; 27(11): 902-906 Letter to the Editor Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type
More informationPart 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD
Week 3: Cardiovascular Disease Learning Outcomes: 1. Define the difference forms of CVD 2. Describe the various risk factors of CVD 3. Describe atherosclerosis and its stages 4. Describe the role of oxidation,
More informationBIOFENOLI ED INIBIZIONE DELL UPTAKE DI oxldl DA PARTE DI CELLULE MACROFAGICHE UMANE E MURINE
BIOFENOLI ED INIBIZIONE DELL UPTAKE DI oxldl DA PARTE DI CELLULE MACROFAGICHE UMANE E MURINE Roberta Di Benedetto Centro Nazionale per la Qualità degli Alimenti e per i Rischi Alimentari Istituto Superiore
More informationCardiovascular Division, Brigham and Women s Hospital, Harvard Medical School
Low Endothelial Shear Stress Upregulates Atherogenic and Inflammatory Genes Extremely Early in the Natural History of Coronary Artery Disease in Diabetic Hyperlipidemic Juvenile Swine Michail I. Papafaklis,
More informationHypertriglyceridemia, Inflammation, & Pregnancy
Hypertriglyceridemia, Inflammation, & Pregnancy Richard L. Nemiroff, MD, FACOG, NLA Professor, Clinical Gynecology Perelman School of Medicine University of Pennsylvania Philadelphia, PA Disclosure of
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationProprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary
Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization
More informationCholesterol (blood, plasma, serum)
1 Cholesterol (blood, plasma, serum) 1 Name and description of analyte 1.1 Name of analyte Cholesterol (plasma; also blood, serum) 1.2 Alternative names 2,15-dimethyl-14-(1,5-dimethylhexyl)tetracyclo[8.7.0.0
More informationEFFECT OF NICARDIPINE ON FASTING PLASMA LIPIDS AND APOLIPOPROTEINS IN MALE NEW ZEALAND WHITE RABBITS. Kamsiah Jaarin, Nafeeza MI*
REVIEW ARTICLE Malaysian Journal of Medical Sciences, Vol. 6, No. 2, July 1999 (5-11) EFFECT OF NICARDIPINE ON FASTING PLASMA LIPIDS AND APOLIPOPROTEINS IN MALE NEW ZEALAND WHITE RABBITS Kamsiah Jaarin,
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationFamilial Hypercholeterolaemia
Familial Hypercholeterolaemia Is it all about statins? Gerald F Watts DSc PhD MD FRACP FRCP Professor and Head, Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital School of Medicine,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationThe Cut-off Point of Interleukin-6 Level in Acute Coronary Syndrome
ORIGINAL ARTICLE The Cut-off Point of Interleukin-6 Level in Acute Coronary Syndrome Idrus Alwi*, T Santoso*, Slamet Suyono**, Bambang Sutrisna***, Siti Boedina Kresno**** ABSTRACT Aim: this study aimed
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.193 Lipid Profile as Early Predictor of Complication
More informationAutonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
More informationPharmacy Management Drug Policy
SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service
More informationSUPPLEMENTAL MATERIAL. Number of patients 14
SUPPLEMENTAL MATERIAL Supplemental Table 1 Number of patients 14 Age, years 54.9 ± 10.0 Female gender, n (%) 6 (42.9) Diabetes, n (%) 2 (14.3) History of hypertension, n (%) 5 (35.7) Ever smoker, n (%)
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationAnne Carol Goldberg, MD, FACP, FAHA, FNLA Washington University, St. Louis, MO USA
Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients with Hypercholesterolemia and High Cardiovascular Risk: The CLEAR Wisdom Trial Anne Carol Goldberg, MD, FACP, FAHA,
More informationInvited Review. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases
Histol Histopathol (2000) 15: 557-571 Histology and Histopathology Cellular and Molecular Biology Invited Review Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular
More informationCho et al., 2009 Journal of Cardiology (2009), 54:
Endothelial Dysfunction, Increased Carotid Artery Intima-media Thickness and Pulse Wave Velocity, and Increased Level of Inflammatory Markers are Associated with Variant Angina Cho et al., 2009 Journal
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationDefining and Controlling Severe Familial Hypercholesterolemia
Defining and Controlling Severe Familial Hypercholesterolemia Raul D. Santos MD, PhD InCor-University of Sao Paulo Hospital Israelita Albert Einstein Brazil 1 Disclosure Honoraria received for consulting,
More informationCardiac Disease Screening Lipid Profile
Cardiac Disease Screening Lipid Profile Date of Origin: 04/2003 Last Review Date: 02/27/2019 Effective Date: 03/01/2019 Dates Reviewed: 01/2004, 04/2005, 12/2005, 06/2006, 06/2007, 07/2008, 6/2011, 05/2012,
More informationLIPOPROTIEN APHERESIS. Bruce Sachais, MD, PhD Executive Medical Director New York Blood Center
LIPOPROTIEN APHERESIS Bruce Sachais, MD, PhD Executive Medical Director New York Blood Center OUTLINE Familial Hypercholesterolemia (FH) Diagnosis Treatment options Lipoprotein apheresis Procedures Expected
More informationWORKSHOP 1. Management of Patients with Familial Hypercholesterolemia
WORKSHOP 1 Management of Patients with Familial Hypercholesterolemia Tutors: Manal Al-Kindi (Oman)/ Gilles Lambert (France) (Case 1) Zuhier Awan (KSA)/ Raul Santos (Brazil) (Case 2) Khalid Al-Waili (Oman)/
More informationLipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry
Lipoproteins Metabolism Reference: Campbell Biochemistry and Lippincott s Biochemistry Learning Objectives 1. Define lipoproteins and explain the rationale of their formation in blood. 2. List different
More informationEmmanouil S. Brilakis 1{, Joseph P. McConnell 2, Ryan J. Lennon 3, Ahmad A. Elesber 1, Jeffrey G. Meyer 2, and Peter B. Berger 4 * Introduction
European Heart Journal (2005) 26, 137 144 doi:10.1093/eurheartj/ehi010 Clinical research Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic
More informationReverse Cholesterol Transport and Atherosclerosis
JCR2014 (2014.12.13@Novotel, Busan, South Korea) Reverse Cholesterol Transport and Atherosclerosis Shizuya Yamashita, MD, PhD, FAHA, FJCC Department of Community Medicine Department ofcardiovascular Medicine
More informationAnnals of RSCB Vol. XVI, Issue 1
THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationEarly Atherosclerotic Markers in Children with Familial Hypercholesterolemia
Early Atherosclerotic Markers in Children with Familial Hypercholesterolemia Master Thesis by Ingunn Narverud Supervisors: Kirsten B. Holven, Marit S. Nenseter and Vibeke H. Telle-Hansen Institute for
More informationCholesterol and Cholesterol Oxides on Coronary Heart Diseases
Cholesterol and Cholesterol Oxides on Coronary Heart Diseases Trends in egg consumption in U.S. and the reason A. Egg Consumption: - 403 in 1945-234 in 1993 (176 Table eggs, 58 Processed eggs) - 256 in
More informationGenetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis
Genetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis Mato Nagel, Ioan Duma, Constantina Vlad, Mandy Benke, Sylvia Nagorka Zentrum für Nephrologie & Stoffwechsel,
More informationNovel function of NADPH oxidase in atherosclerosis. Yun Soo Bae Department of Life Science Ewha Womans University
Novel function of NADPH oxidase in atherosclerosis Yun Soo Bae Department of Life Science Ewha Womans University Recent understanding of ROS: act as second messengers e e Catalase/peroxidase O 2 H 2 O
More informationTracking a Killer Molecule
Tracking a Killer Molecule Mercodia Oxidized LDL ELISA www.mercodia.com Mercodia Oxidized LDL ELISA products Product Catalog No Kit size Oxidized LDL ELISA 10-1143-01 96 wells Oxidized LDL competitive
More informationLipoprotein (a): Is it important for Friedewald formula?
ORIGINAL RESEARCH ALBANIAN MEDICAL JOURNAL Lipoprotein (a): Is it important for Friedewald formula? Murat Can 1, Berrak Guven 1 1 Bulent Ecevit University, Faculty of Medicine, Department of Biochemistry
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationImaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006
Imaging Biomarkers: utilisation for the purposes of registration EMEA-EFPIA Workshop on Biomarkers 15 December 2006 Vascular Imaging Technologies Carotid Ultrasound-IMT IVUS-PAV QCA-% stenosis 2 ICH E
More informationCirculating levels of MCP-1 and eotaxin are not associated with presence of atherosclerosis or previous myocardial infarction
Atherosclerosis 183 (2005) 268 274 Circulating levels of MCP-1 and eotaxin are not associated with presence of atherosclerosis or previous myocardial infarction David E. Mosedale a,b,, Duncan J. Smith
More information